Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib for antioxidant absorption in healthy volunteers
NCT06982508Phase 2Recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing Obicetrapib 10mg with Placebo (2 arms). Primary endpoint: Sum of Percent Change of Antioxidant Levels within HDL at 16 weeks. Started Sep 2025; status: recruiting.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06982508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982508.